Annual Cash & Cash Equivalents
$69.33 M
-$5.72 M-7.63%
December 31, 2024
Summary
- As of March 10, 2025, SUPN annual cash & cash equivalents is $69.33 million, with the most recent change of -$5.72 million (-7.63%) on December 31, 2024.
- During the last 3 years, SUPN annual cash & cash equivalents has fallen by -$134.10 million (-65.92%).
- SUPN annual cash & cash equivalents is now -75.98% below its all-time high of $288.64 million, reached on December 31, 2020.
Performance
SUPN Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$69.33 M
+$37.66 M+118.90%
December 31, 2024
Summary
- As of March 10, 2025, SUPN quarterly cash and cash equivalents is $69.33 million, with the most recent change of +$37.66 million (+118.90%) on December 31, 2024.
- Over the past year, SUPN quarterly cash and cash equivalents has stayed the same.
- SUPN quarterly cash and cash equivalents is now -84.39% below its all-time high of $444.14 million, reached on March 31, 2018.
Performance
SUPN Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
SUPN Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -7.6% | 0.0% |
| 3 y3 years | -65.9% | -27.0% |
| 5 y5 years | -61.8% | -27.0% |
SUPN Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -65.9% | at low | -65.9% | +180.6% |
| 5 y | 5-year | -76.0% | at low | -76.0% | +180.6% |
| alltime | all time | -76.0% | +192.0% | -84.4% | +479.9% |
Supernus Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $69.33 M(-7.6%) | $69.33 M(+118.9%) |
| Sep 2024 | - | $31.67 M(-39.2%) |
| Jun 2024 | - | $52.09 M(-17.8%) |
| Mar 2024 | - | $63.40 M(-15.5%) |
| Dec 2023 | $75.05 M(-19.4%) | $75.05 M(-21.0%) |
| Sep 2023 | - | $94.98 M(+284.5%) |
| Jun 2023 | - | $24.71 M(-57.7%) |
| Mar 2023 | - | $58.44 M(-37.2%) |
| Dec 2022 | $93.12 M(-54.2%) | $93.12 M(-16.5%) |
| Sep 2022 | - | $111.49 M(-35.7%) |
| Jun 2022 | - | $173.43 M(+49.9%) |
| Mar 2022 | - | $115.72 M(-43.1%) |
| Dec 2021 | $203.43 M(-29.5%) | $203.43 M(-5.5%) |
| Sep 2021 | - | $215.28 M(-3.8%) |
| Jun 2021 | - | $223.77 M(-12.5%) |
| Mar 2021 | - | $255.64 M(-11.4%) |
| Dec 2020 | $288.64 M(+59.1%) | $288.64 M(+41.3%) |
| Sep 2020 | - | $204.29 M(-3.2%) |
| Jun 2020 | - | $210.97 M(-6.6%) |
| Mar 2020 | - | $225.77 M(+24.5%) |
| Dec 2019 | $181.38 M(-5.7%) | $181.38 M(+55.2%) |
| Sep 2019 | - | $116.89 M(+33.8%) |
| Jun 2019 | - | $87.34 M(-28.9%) |
| Mar 2019 | - | $122.78 M(-36.1%) |
| Dec 2018 | $192.25 M(+91.7%) | $192.25 M(+55.3%) |
| Sep 2018 | - | $123.82 M(+251.7%) |
| Jun 2018 | - | $35.20 M(-92.1%) |
| Mar 2018 | - | $444.14 M(+342.8%) |
| Dec 2017 | $100.30 M | $100.30 M(+22.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2017 | - | $81.92 M(+32.7%) |
| Jun 2017 | - | $61.74 M(+3.6%) |
| Mar 2017 | - | $59.60 M(-10.2%) |
| Dec 2016 | $66.40 M(+98.2%) | $66.40 M(+22.3%) |
| Sep 2016 | - | $54.30 M(+50.2%) |
| Jun 2016 | - | $36.16 M(+82.3%) |
| Mar 2016 | - | $19.83 M(-40.8%) |
| Dec 2015 | $33.50 M(-8.0%) | $33.50 M(+27.4%) |
| Sep 2015 | - | $26.29 M(-20.6%) |
| Jun 2015 | - | $33.11 M(+28.3%) |
| Mar 2015 | - | $25.81 M(-29.1%) |
| Dec 2014 | $36.40 M(+10.4%) | $36.40 M(-3.7%) |
| Sep 2014 | - | $37.78 M(+216.0%) |
| Jun 2014 | - | $11.96 M(-2.4%) |
| Mar 2014 | - | $12.25 M(-62.9%) |
| Dec 2013 | $32.98 M(-18.2%) | $32.98 M(+43.7%) |
| Sep 2013 | - | $22.95 M(-32.3%) |
| Jun 2013 | - | $33.91 M(+79.3%) |
| Mar 2013 | - | $18.91 M(-53.1%) |
| Dec 2012 | $40.30 M(-17.0%) | $40.30 M(+72.1%) |
| Sep 2012 | - | $23.41 M(-50.4%) |
| Jun 2012 | - | $47.24 M(+197.8%) |
| Mar 2012 | - | $15.87 M(-67.3%) |
| Dec 2011 | $48.54 M(+104.5%) | $48.54 M(+194.5%) |
| Sep 2011 | - | $16.48 M(-30.6%) |
| Dec 2010 | $23.74 M(-24.4%) | $23.74 M(-6.0%) |
| Sep 2010 | - | $25.26 M(-19.6%) |
| Dec 2009 | $31.41 M(-40.6%) | $31.41 M |
| Dec 2008 | $52.88 M | - |
FAQ
- What is Supernus Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Supernus Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Supernus Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of SUPN is $69.33 M
What is the all time high annual cash & cash equivalents for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual cash & cash equivalents is $288.64 M
What is Supernus Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, SUPN annual cash & cash equivalents has changed by -$5.72 M (-7.63%)
What is Supernus Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SUPN is $69.33 M
What is the all time high quarterly cash and cash equivalents for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly cash and cash equivalents is $444.14 M
What is Supernus Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, SUPN quarterly cash and cash equivalents has changed by $0.00 (0.00%)